利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.015 秒)

    VLP Stabilized Vaccine Compositions
    3.
    发明申请
    VLP Stabilized Vaccine Compositions 有权

    公开(公告)号：US20210069318A1

    公开(公告)日：2021-03-11

    申请号：US16988659

    申请日：2020-08-09

    申请人： Inventprise, LLC

    发明人： Subhash V. Kapre

    IPC分类号： A61K39/12 ,  A61K9/00 ,  A61K9/19 ,  A61K47/10 ,  A61K47/42 ,  C07K14/005 ,  C12N7/00

    摘要： The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

    Heat Stable Vaccines
    4.
    发明申请
    Heat Stable Vaccines 审中-公开

    公开(公告)号：US20200009242A1

    公开(公告)日：2020-01-09

    申请号：US16571702

    申请日：2019-09-16

    申请人： Inventprise, LLC

    发明人： Subhash V. Kapre ,  Ivan A. Olave

    IPC分类号： A61K39/15 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K47/14 ,  C12N7/00

    摘要： The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30° C. and 40° C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30° C., and six months at 50° C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.

    Multivalent Conjugate Vaccines with Bivalent or Multivalent Conjugate Polysaccharides that Provide Improved Immunogenicity and Avidity
    5.
    发明申请
    Multivalent Conjugate Vaccines with Bivalent or Multivalent Conjugate Polysaccharides that Provide Improved Immunogenicity and Avidity 审中-公开

    公开(公告)号：US20180353591A1

    公开(公告)日：2018-12-13

    申请号：US16004743

    申请日：2018-06-11

    申请人： Inventprise, LLC

    发明人： Subhash V. Kapre ,  Anup K. Datta

    IPC分类号： A61K39/09

    摘要： The disclosure describes compositions containing conjugates using novel linkers, bivalent polysaccharide conjugates, and methods of bivalent polysaccharide conjugation in the development of multivalent conjugate vaccines. Conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of the linkers and their use in bifunctional linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are conjugated sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups. Such a linker and the size of the capsular polysaccharides provides an effective multivalent conjugate vaccine with high antibody titers and a reduced carrier effect and results in reduction in the content of the capsular polysaccharide and protein per dose of vaccine which reduces reactogenicity.

    Mixtures of Polysaccharide Protein Pegylated Compounds
    7.
    发明申请
    Mixtures of Polysaccharide Protein Pegylated Compounds 有权

    公开(公告)号：US20210113686A1

    公开(公告)日：2021-04-22

    申请号：US16984145

    申请日：2020-08-03

    申请人： Inventprise, LLC

    发明人： Subhash V. Kapre ,  Anup K. Datta

    IPC分类号： A61K39/385 ,  A61K39/09

    摘要： The disclosure describes compositions containing PEGylated compounds using linkers, bivalent polysaccharide covalent PEG compounds, and methods of bivalent polysaccharide-PEG compounds in the development of multivalent vaccines. PEGylated conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of bifunctional PEG linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are covalently PEG compounded sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups. Such a linker and the size of the capsular polysaccharides provides an effective multivalent vaccine with high antibody titers and a reduced carrier effect, with a reduction in the content of the capsular polysaccharide and protein per dose of vaccine which reduces reactogenicity.

    VLP stabilized vaccine compositions
    8.
    发明授权
    VLP stabilized vaccine compositions 有权

    公开(公告)号：US10758606B2

    公开(公告)日：2020-09-01

    申请号：US15257143

    申请日：2016-09-06

    申请人： Inventprise, LLC

    发明人： Subhash V. Kapre

    IPC分类号： A61K39/29 ,  A61K39/295 ,  A61K47/42 ,  C07K14/025 ,  A61K39/12 ,  A61K9/00 ,  A61K9/19 ,  A61K47/10 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

    摘要： The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

    Polysaccharide Purification for Vaccine Production using Lytic Enzymes, Tangential Flow Filtration, and Multimode Chromatography
    10.
    发明申请
    Polysaccharide Purification for Vaccine Production using Lytic Enzymes, Tangential Flow Filtration, and Multimode Chromatography 审中-公开

    公开(公告)号：US20200023050A1

    公开(公告)日：2020-01-23

    申请号：US16585385

    申请日：2019-09-27

    申请人： Inventprise, LLC

    发明人： Subhash V. Kapre ,  Anup K. Datta

    IPC分类号： A61K39/09 ,  A61K39/102 ,  A61K39/112 ,  A61K39/095

    摘要： An improved, cost effective and shortened process of purification of the capsular polysaccharide of S. pneumoniae, Group B Streptococcus, H. influenzae, S. typhoid and N. meningitidis is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.